Development of PI3K inhibitors: lessons learned from early clinical trialsJordi Rodon
Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain
Nat Rev Clin Oncol 10:143-53. 2013
..We also discuss key unresolved translational questions related to the clinical development of inhibitors of the PI3K/AKT/mTOR pathway and propose designs for biomarker-driven trials to address those issues...
- Molecular prescreening to select patient population in early clinical trials
Jordi Rodon
Medical Oncology Department, Vall d Hebron University Hospital, Spain
Nat Rev Clin Oncol 9:359-66. 2012
....
Combining targeted therapies: practical issues to consider at the bench and bedsideJordi Rodon
Servei d Oncologia Medica, Hospital Universitari Vall d Hebron, Vall d Hebron Institute of Oncology V H I O, Passatge Vall d Hebron 119, 08035 Barcelona, Spain
Oncologist 15:37-50. 2010
..Recent technologies, such as multiplexed assay platforms and bioinformatics, will shape the future of clinical trials and help answer these questions surrounding combinatorial treatment...
- A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
Francesco Atzori
Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Clin Cancer Res 17:6304-12. 2011
..This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose...
- Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
Rodrigo Dienstmann
Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Mol Cancer Ther 11:2062-71. 2012
..2%). These results suggest that matching chemorefractory patients with colorectal cancer with targeted agents in phase I trials based on the current molecular profile does not confer a significant clinical benefit...
- Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
Rodrigo Dienstmann
Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Oncologist 16:1729-40. 2011
..Ultimately, the predictive value of a side effect of molecular targeted therapies requires validation in prospective trials...
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2Rodrigo Dienstmann
Medical Oncology Service, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain
Recent Pat Anticancer Drug Discov 6:210-36. 2011
..This review will focus primarily on an analysis of newly developed inhibitors of this pathway that have entered clinical trials, and recently registered patents in this field...
- Biomarker-driven patient selection for early clinical trials
Rodrigo Dienstmann
Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
Curr Opin Oncol 25:305-12. 2013
..Technical and logistical obstacles that may hinder progress of this approach will be discussed, along with the ethical and financial concerns...
